查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1802041

再生医疗的全球市场:各产品类型，各材料，各基因改造材料，各用途，各终端用户，各地区，市场规模，产业趋势，机会分析与预测(2025年～2033年)

Global Regenerative Medicine Market: Product Type, Material, Genetically Engineered Material, Application, End Users, Region Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 300 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

再生医学市场正在经历显着扩张，一些预测显示，未来十年其全球估值将大幅上升。 2024 年，市场规模约为 730.1 亿美元，预计到 2033 年将飙升至 5,785.9 亿美元。 2025 年至 2033 年，此成长的复合年增长率为 25.86%。这一惊人成长主要得益于干细胞疗法、基因编辑和组织工程等关键技术的重大进步。

然而，市场成长受制于显着的地区差异，这会影响投资速度和患者获得治疗的机会。北美仍处于领先地位，受益于其最发达的再生疗法临床基础设施。到2024年中期，约有400家专业机构将获得自体细胞治疗认证，这将证明该地区在提供个人化再生医学方面的先进能力。此外，美国已有八个州颁布立法，强制推行基于价值的合同，这有助于减轻这些创新疗法高昂的前期成本带来的财务负担。此类监管和临床框架支持可持续的采用和报销模式，使更广泛的患者能够获得治疗。

值得关注的市场发展

再生医学市场的竞争格局由老牌生物製药巨头主导，他们利用尖端技术推动创新并扩大全球影响力。美敦力公司是该领域的领导者，业务遍及150多个国家，约有9万名专业人员。广泛的全球影响力使美敦力能够利用多元化的市场和专业知识，并始终站在再生医学发展的前沿。

其他影响市场的关键参与者包括艾伯维公司 (AbbVie Inc.)、安进公司 (Amgen Inc.) 和诺华製药公司 (Novartis Pharma AG)，它们均在研发方面投入大量资金。这些公司不断突破再生医学的界限，推动突破性进展，以应对各种疾病。他们对研发的投入推动了一系列创新，并确保了持续不断的新型疗法，从而改善病患照护。

核心推动因素

再生医学市场目前正经历前所未有的监管审批激增，这些发展正在从根本上改变全球数百万患者的治疗途径。到2024年，主要国际市场的监管机构都将加快审批流程，以跟上再生疗法的快速发展。美国食品药物管理局 (FDA) 尤其发挥关键作用，光是今年前三个季度，就已将突破性疗法认定授予了超过15种新型细胞和基因疗法。

同样，日本医药品医疗器材综合机构 (PMDA) 也继续以其渐进式有条件审批框架树立全球标准。这种监管方式允许再生医学产品在安全性和有效性得到证明后，即使仍在收集全面的疗效数据，也能提前进入市场。这项政策不仅鼓励创新，也有助于患者快速获得可能改变人生的疗法。

新机会中的趋势

人工智慧 (AI) 与再生医学的融合，利用前所未有的计算能力，从根本上改变了治疗开发时间表和患者预后。这种融合涵盖了整个再生医学价值链，从最初的发现和研究到製造优化和持续的患者监测。人工智慧能够快速且准确地分析大量资料集，从而加速识别新的治疗靶点，优化复杂的製造流程，并实现即时、个人化的患者护理。

人工智慧在再生医学领域的实际应用展现了其对临床实践的变革性影响。例如，麻省总医院实施了一套由人工智慧驱动的监测系统，持续追踪3500名接受干细胞治疗的患者的健康状况。此创新系统可在临床症状出现前72小时内检测到移植排斥的早期迹象，从而能够及时干预，显着改善患者的预后。

优化障碍

製造课题是扩大再生医学市场的最大障碍，儘管获准的疗法数量不断增加，但这仍然严重限制了患者的可及性。先进的细胞和基因疗法的生产非常复杂，需要专门的设施并严格遵守良好生产规范 (GMP)，每条生产线的资本投入超过2.5亿美元。除了这些初始成本外，每位患者的治疗费用约为8.5万美元，而且营运成本仍然很高。

这些资金和技术障碍对扩大生产以满足激增的需求构成了重大瓶颈。其中最显着的阻碍因素之一在于病毒载体的生产，而病毒载体是许多基因疗法的重要组成部分。目前，全球产能每年仅能满足约3.5万例患者的需求。与预期的18万例治疗需求相比，这数字远远不足。这种短缺对及时为患者提供改变命运的治疗方案构成了重大障碍。

详细的市场区隔

按产品类型划分，干细胞疗法将继续主导全球再生医学市场，在2024年至2025年期间占34.64%的显着占有率。这一强劲的市场地位得益于突破性的临床应用以及干细胞技术提供的治疗能力的持续扩展。在这些进步中，诱导多能干细胞 (iPSC) 技术脱颖而出，成为一项突破性进展，显着扩展了干细胞治疗的范围和有效性。 iPSC 是将成体细胞重新编程为胚胎状态，从而能够生成各种特化细胞，为治疗复杂疾病提供了前所未有的可能性。

按材料类型划分，生物衍生材料在再生医学市场占主导地位，在 2024 年至 2025 年期间占了高达 54.77% 的市场占有率，预计复合年增长率 (CAGR) 最高可达 26.30%。这种领先地位源于生物材料无与伦比的生物相容性和治疗功效，使其成为各种再生应用的首选。该领域的主导地位在细胞外基质 (ECM) 技术的突破性进展中尤为明显。 ECM 为组织修復和再生提供必要的支架和生物活性讯号。

从应用角度来看，肿瘤学继续在再生医学市场占主导地位，预计在2024年至2025年期间将占49.22%的市场占有率。这种主导地位主要归功于CAR-T细胞疗法和其他创新癌症疗法等突破性进展，这些疗法显着改善了患者的预后。这些突破代表了血液系统恶性肿瘤和某些实体肿瘤治疗的范式转变，为此前治疗选择有限的患者带来了新的希望。

从最终用户角度来看，医院和诊所已牢固确立了其在再生医学市场中的主导地位，在2024年至2025年期间占了43.57%的显着市场占有率。这一令人印象深刻的地位得益于26.37%的强劲复合年增长率，突显了再生医学在这些医疗环境中的快速扩张和日益普及。作为先进再生疗法的主要交付中心，医院和诊所正在全球进行大量基础设施投资，总额超过 85 亿美元。

各市场区隔明细

各产品类型

  • 基因治疗
  • 细胞疗法
  • 干细胞疗法
    • 自体疗法
    • 同类疗法
  • 组织工程
  • 低分子·生技药品
  • 其他

各材料

  • 合成材料
    • 生物分解性合成聚合物
    • 鹰架
    • 人工血管移植
    • 水凝胶材料
    • 其他
  • 生物来源材料
    • 胶原蛋白
    • 异种材料
    • 其他
  • 基因重组材料
    • 遗传基因操作细胞
    • 基因转殖
    • 纤维母细胞
    • 神经干细胞
    • 遗传基因活性化矩阵
    • 其他
  • 医药品
    • 生技药品
    • 低分子医药品
    • 其他

各用途

  • 皮肤科学
  • 肌肉骨骼系统
  • 免疫·发炎
  • 肿瘤学
  • 心臟血管
  • 神经学
  • 眼科
  • 其他

各终端用户

  • 医院·诊所
  • 专门中心
  • 政府·学术研究机关
  • 其他

各地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 波兰
    • 俄罗斯
    • 其他
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲·纽西兰
    • ASEAN
      • 马来西亚
      • 新加坡
      • 泰国
      • 印尼
      • 菲律宾
      • 越南
      • 其他
    • 其他地区
  • 中东·非洲
    • 阿拉伯联合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他
  • 南美
    • 阿根廷
    • 巴西
    • 其他

市场参与企业

  • Allergan PLC
  • Baxter International Inc
  • Bayer AG
  • Boehringer Ingelheim
  • Cesca Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Corporation
  • Medtronic plc
  • Merck KGaA
  • Mimedx Group Inc
  • Novartis AG
  • Organogenesis, Inc.
  • Osiris Therapeutics
  • Pfizer, Inc.
  • Takara Bio Inc.
  • U.S. Stem Cell, Inc.
  • 其他的主要企业

目录

第1章 调查架构

第2章 调查手法

第3章 摘要整理:全球再生医疗市场

第4章 全球再生医疗市场概要

  • 产业价值链分析
    • 材料供应商
    • 厂商
    • 批发商
    • 终端用户
  • 再生医疗的供应链
    • 细胞的采购与收集
    • 品管与试验
    • 製造及加工
    • 临床试验与法规当局的认证
    • 患者管理
    • 上市后监测
  • 产业展望
  • 大环境分析
  • 波特的五力分析
  • 市场动态和趋势
  • COVID-19对市场成长趋势的影响评估
  • 市场成长与展望
  • 竞争仪表板

第5章 全球再生医疗市场分析(各产品类型)

  • 重要的洞察
  • 市场规模与预测，2020年～2033年(10亿美元)
    • 基因治疗
    • 细胞疗法
    • 干细胞疗法
    • 组织工程
    • 低分子化合物及生技药品
    • 其他

第6章 全球再生医疗市场分析(各材料)

  • 重要的洞察
  • 市场规模与预测，2020年～2033年(10亿美元)
    • 合成材料
    • 生物来源材料
    • 基因改造材料
    • 医药品

第7章 全球再生医疗市场分析(各用途)

  • 重要的洞察
  • 市场规模与预测，2020年～2033年(10亿美元)
    • 皮肤科
    • 肌肉骨骼
    • 免疫学和发炎
    • 肿瘤学
    • 心血管系统
    • 神经学
    • 眼科
    • 其他

第8章 全球再生医疗市场分析(各终端用户)

  • 重要的洞察
  • 市场规模与预测，2020年～2033年(10亿美元)
    • 医院和诊疗所
    • 专门中心
    • 政府及学术调查机关
    • 其他

第9章 全球再生医疗市场分析(各地区)

  • 重要的洞察
  • 市场规模与预测，2020年～2033年(10亿美元)
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第10章 北美的再生医疗市场分析

第11章 美国的再生医疗市场分析

第12章 加拿大的再生医疗市场分析

第13章 墨西哥的再生医疗市场分析

第14章 欧洲的再生医疗市场分析

第15章 英国的再生医疗16.1.重要的洞察

第16章 德国的再生医疗市场分析

第17章 法国的再生医疗市场分析

第18章 义大利的再生医疗市场分析

第19章 西班牙的再生医疗市场分析

第20章 波兰的再生医疗市场分析

第21章 俄罗斯的再生医疗市场分析

第22章 其他的欧洲的再生医疗市场分析

第23章 亚太地区的再生医疗市场分析

第24章 中国的再生医疗市场分析

第25章 印度的再生医疗市场分析

第26章 日本的再生医疗市场分析

第27章 韩国的再生医疗市场分析

第28章 澳洲和纽西兰的再生医疗市场分析

第29章 ASEAN的再生医疗市场分析

第30章 其他的亚太地区的再生医疗市场分析

第31章 中东·非洲的再生医疗市场分析

第32章 UAE的再生医疗市场分析

第33章 沙乌地阿拉伯的再生医疗市场分析

第34章 南非的再生医疗市场分析

第35章 其他的中东·非洲的再生医疗市场分析

第36章 南美的再生医疗市场分析

第37章 阿根廷的再生医疗市场分析

第38章 巴西的再生医疗市场分析

第39章 其他的南美的再生医疗市场分析

第40章 企业简介

  • Allergan PLC
  • Baxter International Inc
  • Bayer AG
  • Boehringer Ingelheim
  • Cesca Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Corporation
  • Medtronic plc
  • Merck KGaA
  • Mimedx Group Inc
  • Novartis AG
  • Organogenesis, Inc.
  • Osiris Therapeutics
  • Pfizer, Inc.
  • Takara Bio Inc.
  • US Stem Cell, Inc.
  • Other Prominent Players
简介目录
Product Code: AA1023640

The regenerative medicine market is undergoing remarkable expansion, with projections indicating a dramatic rise in its global valuation over the coming decade. In 2024, the market was valued at approximately US$ 73.01 billion, and this figure is expected to surge to an estimated US$ 578.59 billion by 2033. This growth corresponds to a robust compound annual growth rate (CAGR) of 25.86% during the forecast period from 2025 to 2033. Such an impressive trajectory is primarily driven by significant advancements in key technologies like stem cell therapy, gene editing, and tissue engineering.

The market's growth, however, is characterized by notable regional disparities that influence the pace of investment and patient access to therapies. North America remains at the forefront, benefiting from the most developed clinical infrastructure for regenerative treatments. By mid-2024, approximately 400 specialized centers had received certification to administer autologous cell therapies, underscoring the region's advanced capabilities in delivering personalized regenerative care. Furthermore, eight U.S. states had enacted legislation mandating value-based agreements, which help mitigate the financial burden of high upfront costs associated with these innovative treatments. This regulatory and clinical framework supports sustainable adoption and reimbursement models, enabling broader patient access.

Noteworthy Market Developments

The competitive landscape of the regenerative medicine market is dominated by well-established biopharmaceutical giants who are harnessing cutting-edge technologies to drive innovation and expand their global reach. Medtronic Plc stands out as a leader, with operations spanning over 150 countries and a workforce of approximately 90,000 professionals. This extensive global presence enables Medtronic to leverage diverse markets and expertise, positioning the company at the forefront of regenerative medicine advancements.

Other major players shaping the market include AbbVie Inc., Amgen Inc., and Novartis Pharma AG, each distinguished by their substantial investments in research and development. These companies continuously push the boundaries of regenerative therapies, driving breakthroughs that address a wide range of medical conditions. Their commitment to R&D fuels innovation pipelines, ensuring a steady flow of novel treatments that enhance patient care.

Core Growth Drivers

The regenerative medicine market is currently experiencing an unprecedented surge in regulatory approvals, a development that is fundamentally reshaping therapeutic accessibility for millions of patients around the globe. Throughout 2024, regulatory agencies across key international markets have accelerated their approval processes to keep pace with the rapid advancements in regenerative therapies. In particular, the U.S. Food and Drug Administration (FDA) has played a pivotal role by granting breakthrough therapy designations to more than 15 novel cell and gene therapies within just the first three quarters of the year.

Similarly, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) continues to set a global standard with its progressive conditional approval framework. This regulatory approach allows regenerative medicine products to enter the market early once they have demonstrated safety and a probable benefit, even if comprehensive efficacy data is still being collected. This policy not only encourages innovation but also facilitates faster patient access to potentially life-changing treatments.

Emerging Opportunity Trends

The convergence of artificial intelligence (AI) with regenerative medicine is fundamentally transforming therapeutic development timelines and patient outcomes by leveraging unprecedented computational power. This integration spans the entire regenerative medicine value chain, from initial discovery and research to manufacturing optimization and ongoing patient monitoring. AI's ability to analyze vast datasets rapidly and accurately is accelerating the identification of novel therapeutic targets, optimizing complex manufacturing processes, and enabling real-time, personalized patient care.

Real-world applications of AI within regenerative medicine illustrate its transformative impact on clinical practice. For instance, Massachusetts General Hospital has implemented an AI-driven monitoring system that continuously tracks the health status of 3,500 patients undergoing stem cell therapy. This innovative system is capable of detecting early signs of transplant rejection up to 72 hours before symptoms become clinically apparent, allowing for timely interventions that significantly improve patient outcomes.

Barriers to Optimization

Manufacturing challenges represent the most formidable obstacle to the expansion of the regenerative medicine market, significantly limiting patient access despite a growing number of therapeutic approvals. The complexity of producing advanced cell and gene therapies demands specialized facilities that comply with stringent Good Manufacturing Practice (GMP) standards, requiring capital investments exceeding US$ 250 million for each production line. In addition to these upfront costs, operational expenses remain exceptionally high, with treatment costs reaching approximately US$ 85,000 per patient.

These financial and technical barriers create significant bottlenecks in scaling production to meet the rapidly increasing demand. One of the most critical constraints lies in the production of viral vectors, which are essential components for many gene therapies. Currently, global manufacturing capacity can only accommodate around 35,000 patient doses annually, a figure vastly insufficient compared to the estimated demand of 180,000 treatments. This shortfall presents a major hurdle in delivering life-changing therapies to patients in a timely manner.

Detailed Market Segmentation

By Product Type, stem cell therapy continues to hold a dominant position in the global regenerative medicine market, capturing a significant 34.64% share during the 2024-2025 period. This strong market presence is fueled by groundbreaking clinical applications and the ongoing expansion of therapeutic capabilities that stem cell technologies offer. Among these advances, induced pluripotent stem cell (iPSC) technology stands out as a revolutionary development that has significantly broadened the scope and effectiveness of stem cell therapies. iPSCs, which are adult cells reprogrammed to an embryonic-like state, enable the generation of a wide variety of specialized cell types, offering unprecedented potential for treating complex diseases.

By Material, biologically derived materials hold a dominant position in the regenerative medicine market, commanding an impressive 54.77% share during 2024-2025 and projecting the highest compound annual growth rate (CAGR) of 26.30%. This leadership is rooted in the unparalleled biocompatibility and therapeutic efficacy that biologically sourced materials offer, making them the preferred choice for a wide range of regenerative applications. The segment's prominence is particularly evident in the groundbreaking advancements in extracellular matrix (ECM) technologies, which provide essential scaffolding and bioactive cues to support tissue repair and regeneration.

By Application, the oncology segment continues to hold a commanding position in the regenerative medicine market, capturing a substantial 49.22% share during the 2024-2025 period. This dominance is largely driven by revolutionary advancements such as CAR-T cell therapies and other innovative cancer treatment modalities that are dramatically improving patient outcomes. These breakthroughs represent a paradigm shift in how hematological malignancies and certain solid tumors are treated, offering new hope to patients who previously had limited options.

By End Users, hospitals and clinics have firmly established themselves as the dominant end users in the regenerative medicine market, commanding a significant market share of 43.57% during 2024-2025. This impressive position is underpinned by a robust compound annual growth rate (CAGR) of 26.37%, highlighting the rapid expansion and increasing adoption of regenerative medicine within these healthcare settings. As primary delivery centers for advanced regenerative therapies, hospitals and clinics have been making substantial infrastructure investments worldwide, totaling over US$ 8.5 billion.

Segment Breakdown

By Product Type

  • Gene Therapy
  • Cell Therapy
  • Stem Cell Therapy
    • Autologous Therapy
    • Allogenic Therapy
  • Tissue-Engineering
  • Small Molecules & Biologics
  • Others

By Material

  • Synthetic material
    • Biodegradable synthetic polymers
    • Scaffold
    • Artificial Vascular Graft
    • Hydrogel Material
    • Others
  • Biologically derived material
    • Collagen
    • Xenogeneic material
    • Others
  • Genetically Engineered Material
    • Genetically Manipulated Cell
    • Transgenics
    • Fibroblast
    • Neural Stem Cell
    • Gene-Activated Matrices
    • Others
  • Pharmaceutical
    • Biologics
    • Small Molecules
    • Others

By Application

  • Dermatology
  • Musculoskeletal
  • Immunology & Inflammation
  • Oncology
  • Cardiovascular
  • Neurology
  • Ophthalmology
  • Others

By End User

  • Hospitals & Clinics
  • Speciality Centers
  • Government & Academic Research Institutes
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Poland
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia & New Zealand
    • ASEAN
      • Malaysia
      • Singapore
      • Thailand
      • Indonesia
      • Philippines
      • Vietnam
      • Rest of ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of MEA
  • South America
    • Argentina
    • Brazil
    • Rest of South America

Leading Market Participants

  • Allergan PLC
  • Baxter International Inc
  • Bayer AG
  • Boehringer Ingelheim
  • Cesca Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Corporation
  • Medtronic plc
  • Merck KGaA
  • Mimedx Group Inc
  • Novartis AG
  • Organogenesis, Inc.
  • Osiris Therapeutics
  • Pfizer, Inc.
  • Takara Bio Inc.
  • U.S. Stem Cell, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Regenerative Medicine Market

Chapter 4. Global Regenerative Medicine Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Supply chain of regenerative medicine
    • 4.2.1. Cell Sourcing and Collection
    • 4.2.2. Quality Control and Testing
    • 4.2.3. Manufacturing and Processing
    • 4.2.4. Clinical Trials and Regulatory Approval
    • 4.2.5. Patient Administration
    • 4.2.6. Post-Market Surveillance
  • 4.3. Industry Outlook
    • 4.3.1. Advances in Regenerative Medicine and Tissue Engineering
    • 4.3.2. Regulation of Regenerative Medicine in Japan
    • 4.3.3. Dissemination of Regenerative Medicine in Japan
    • 4.3.4. Overview: Japan Strengthens Regenerative Medicine Oversight
    • 4.3.5. Regenerative Medicine at a Global Level: Current Patterns and Global Trends
    • 4.3.6. Comparative lessons in regenerative medicine readiness: UK and Japan Case Study
    • 4.3.7. A comparative analysis of attitudes toward stem cell research and regenerative medicine between six countries (Japan, South Korea, the USA, the UK, Germany, and France)
  • 4.4. PESTLE Analysis
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of Substitutes
    • 4.5.4. Threat of New Entrants
    • 4.5.5. Degree of Competition
  • 4.6. Market Dynamics and Trends
    • 4.6.1. Growth Drivers
    • 4.6.2. Restraints
    • 4.6.3. Challenges
    • 4.6.4. Key Trend
  • 4.7. Covid-19 Impact Assessment on Market Growth Trend
  • 4.8. Market Growth and Outlook
    • 4.8.1. Market Revenue Estimates and Forecast (US$ Bn), 2020 - 2033
    • 4.8.2. Price Trend Analysis, By Product Type
  • 4.9. Competition Dashboard
    • 4.9.1. Market Concentration Rate
    • 4.9.2. Company Market Share Analysis (Value %), 2024
    • 4.9.3. Competitor Mapping

Chapter 5. Global Regenerative Medicine Market Analysis, By Product Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 5.2.1. Gene Therapy
    • 5.2.2. Cell Therapy
    • 5.2.3. Stem Cell Therapy
      • 5.2.3.1. Autologous Therapy
      • 5.2.3.2. Allogenic Therapy
    • 5.2.4. Tissue-Engineering
    • 5.2.5. Small Molecules & Biologics
    • 5.2.6. Others

Chapter 6. Global Regenerative Medicine Market Analysis, By Material

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 6.2.1. Synthetic material
      • 6.2.1.1. Biodegradable synthetic polymers
      • 6.2.1.2. Scaffold
      • 6.2.1.3. Artificial Vascular Graft
      • 6.2.1.4. Hydrogel Material
      • 6.2.1.5. Others
    • 6.2.2. Biologically derived material
      • 6.2.2.1. Collagen
      • 6.2.2.2. Xenogeneic material
      • 6.2.2.3. Others
    • 6.2.3. Genetically Engineered Material
      • 6.2.3.1. Genetically Manipulated Cell
      • 6.2.3.2. Transgenics
      • 6.2.3.3. Fibroblast
      • 6.2.3.4. Neural Stem Cell
      • 6.2.3.5. Gene-Activated Matrices
      • 6.2.3.6. Others
    • 6.2.4. Pharmaceutical
      • 6.2.4.1. Biologics
      • 6.2.4.2. Small Molecules
      • 6.2.4.3. Others

Chapter 7. Global Regenerative Medicine Market Analysis, By Application

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 7.2.1. Dermatology
    • 7.2.2. Musculoskeletal
    • 7.2.3. Immunology & Inflammation
    • 7.2.4. Oncology
    • 7.2.5. Cardiovascular
    • 7.2.6. Neurology
    • 7.2.7. Ophthalmology
    • 7.2.8. Others

Chapter 8. Global Regenerative Medicine Market Analysis, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 8.2.1. Hospitals & Clinics
    • 8.2.2. Speciality Centers
    • 8.2.3. Government & Academic Research Institutes
    • 8.2.4. Others

Chapter 9. Global Regenerative Medicine Market Analysis, By Region

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 9.2.1. North America
      • 9.2.1.1. The U.S.
      • 9.2.1.2. Canada
      • 9.2.1.3. Mexico
    • 9.2.2. Europe
        • 9.2.2.1.1. The UK
        • 9.2.2.1.2. Germany
        • 9.2.2.1.3. France
        • 9.2.2.1.4. Italy
        • 9.2.2.1.5. Spain
        • 9.2.2.1.6. Poland
        • 9.2.2.1.7. Russia
        • 9.2.2.1.8. Rest of Europe
    • 9.2.3. Asia Pacific
      • 9.2.3.1. China
      • 9.2.3.2. India
      • 9.2.3.3. Japan
      • 9.2.3.4. South Korea
      • 9.2.3.5. Australia & New Zealand
      • 9.2.3.6. ASEAN
      • 9.2.3.7. Rest of Asia Pacific
    • 9.2.4. Middle East & Africa
      • 9.2.4.1. UAE
      • 9.2.4.2. Saudi Arabia
      • 9.2.4.3. South Africa
      • 9.2.4.4. Rest of MEA
    • 9.2.5. South America
      • 9.2.5.1. Argentina
      • 9.2.5.2. Brazil
      • 9.2.5.3. Rest of South America

Chapter 10. North America Regenerative Medicine Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 10.2.1. By Product Type
    • 10.2.2. By Material
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country

Chapter 11. The U.S. Regenerative Medicine Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 11.2.1. By Product Type
    • 11.2.2. By Material
    • 11.2.3. By Application
    • 11.2.4. By End User

Chapter 12. Canada Regenerative Medicine Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 12.2.1. By Product Type
    • 12.2.2. By Material
    • 12.2.3. By Application
    • 12.2.4. By End User

Chapter 13. Mexico Regenerative Medicine Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 13.2.1. By Product Type
    • 13.2.2. By Material
    • 13.2.3. By Application
    • 13.2.4. By End User

Chapter 14. Europe Regenerative Medicine Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 14.2.1. By Product Type
    • 14.2.2. By Material
    • 14.2.3. By Application
    • 14.2.4. By End User
    • 14.2.5. By Country

Chapter 15. The UK Regenerative Medicine 16.1. Key Insights

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 15.2.1. By Product Type
    • 15.2.2. By Material
    • 15.2.3. By Application
    • 15.2.4. By End User

Chapter 16. Germany Regenerative Medicine Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 16.2.1. By Product Type
    • 16.2.2. By Material
    • 16.2.3. By Application
    • 16.2.4. By End User

Chapter 17. France Regenerative Medicine Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 17.2.1. By Product Type
    • 17.2.2. By Material
    • 17.2.3. By Application
    • 17.2.4. By End User

Chapter 18. Italy Regenerative Medicine Market Analysis

  • 18.1. Key Insights
  • 18.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 18.2.1. By Product Type
    • 18.2.2. By Material
    • 18.2.3. By Application
    • 18.2.4. By End User

Chapter 19. Spain Regenerative Medicine Market Analysis

  • 19.1. Key Insights
  • 19.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 19.2.1. By Product Type
    • 19.2.2. By Material
    • 19.2.3. By Application
    • 19.2.4. By End User

Chapter 20. Poland Regenerative Medicine Market Analysis

  • 20.1. Key Insights
  • 20.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 20.2.1. By Product Type
    • 20.2.2. By Material
    • 20.2.3. By Application
    • 20.2.4. By End User

Chapter 21. Russia Regenerative Medicine Market Analysis

  • 21.1. Key Insights
  • 21.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 21.2.1. By Product Type
    • 21.2.2. By Material
    • 21.2.3. By Application
    • 21.2.4. By End User

Chapter 22. Rest of Europe Regenerative Medicine Market Analysis

  • 22.1. Key Insights
  • 22.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 22.2.1. By Product Type
    • 22.2.2. By Material
    • 22.2.3. By Application
    • 22.2.4. By End User

Chapter 23. Asia Pacific Regenerative Medicine Market Analysis

  • 23.1. Key Insights
  • 23.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 23.2.1. By Product Type
    • 23.2.2. By Material
    • 23.2.3. By Application
    • 23.2.4. By End User
    • 23.2.5. By Country

Chapter 24. China Regenerative Medicine Market Analysis

  • 24.1. Key Insights
  • 24.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 24.2.1. By Product Type
    • 24.2.2. By Material
    • 24.2.3. By Application
    • 24.2.4. By End User

Chapter 25. India Regenerative Medicine Market Analysis

  • 25.1. Key Insights
  • 25.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 25.2.1. By Product Type
    • 25.2.2. By Material
    • 25.2.3. By Application
    • 25.2.4. By End User

Chapter 26. Japan Regenerative Medicine Market Analysis

  • 26.1. Key Insights
  • 26.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 26.2.1. By Product Type
    • 26.2.2. By Material
    • 26.2.3. By Application
    • 26.2.4. By End User

Chapter 27. South Korea Regenerative Medicine Market Analysis

  • 27.1. Key Insights
  • 27.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 27.2.1. By Product Type
    • 27.2.2. By Material
    • 27.2.3. By Application
    • 27.2.4. By End User

Chapter 28. Australia & New Zealand Regenerative Medicine Market Analysis

  • 28.1. Key Insights
  • 28.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 28.2.1. By Product Type
    • 28.2.2. By Material
    • 28.2.3. By Application
    • 28.2.4. By End User

Chapter 29. ASEAN Regenerative Medicine Market Analysis

  • 29.1. Key Insights
  • 29.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 29.2.1. By Product Type
    • 29.2.2. By Material
    • 29.2.3. By Application
    • 29.2.4. By End User

Chapter 30. Rest of Asia Pacific Regenerative Medicine Market Analysis

  • 30.1. Key Insights
  • 30.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 30.2.1. By Product Type
    • 30.2.2. By Material
    • 30.2.3. By Application
    • 30.2.4. By End User

Chapter 31. Middle East and Africa Regenerative Medicine Market Analysis

  • 31.1. Key Insights
  • 31.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 31.2.1. By Product Type
    • 31.2.2. By Material
    • 31.2.3. By Application
    • 31.2.4. By End User
    • 31.2.5. By Country

Chapter 32. UAE Regenerative Medicine Market Analysis

  • 32.1. Key Insights
  • 32.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 32.2.1. By Product Type
    • 32.2.2. By Material
    • 32.2.3. By Application
    • 32.2.4. By End User

Chapter 33. Saudi Arabia Regenerative Medicine Market Analysis

  • 33.1. Key Insights
  • 33.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 33.2.1. By Product Type
    • 33.2.2. By Material
    • 33.2.3. By Application
    • 33.2.4. By End User

Chapter 34. South Africa Regenerative Medicine Market Analysis

  • 34.1. Key Insights
  • 34.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 34.2.1. By Product Type
    • 34.2.2. By Material
    • 34.2.3. By Application
    • 34.2.4. By End User

Chapter 35. Rest of MEA Regenerative Medicine Market Analysis

  • 35.1. Key Insights
  • 35.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 35.2.1. By Product Type
    • 35.2.2. By Material
    • 35.2.3. By Application
    • 35.2.4. By End User

Chapter 36. South America Regenerative Medicine Market Analysis

  • 36.1. Key Insights
  • 36.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 36.2.1. By Product Type
    • 36.2.2. By Material
    • 36.2.3. By Application
    • 36.2.4. By End User
    • 36.2.5. By Country

Chapter 37. Argentina Regenerative Medicine Market Analysis

  • 37.1. Key Insights
  • 37.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 37.2.1. By Product Type
    • 37.2.2. By Material
    • 37.2.3. By Application
    • 37.2.4. By End User

Chapter 38. Brazil Regenerative Medicine Market Analysis

  • 38.1. Key Insights
  • 38.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 38.2.1. By Product Type
    • 38.2.2. By Material
    • 38.2.3. By Application
    • 38.2.4. By End User

Chapter 39. Rest of South America Regenerative Medicine Market Analysis

  • 39.1. Key Insights
  • 39.2. Market Size and Forecast, 2020 - 2033 (US$ Bn)
    • 39.2.1. By Product Type
    • 39.2.2. By Material
    • 39.2.3. By Application
    • 39.2.4. By End User

Chapter 40. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 40.1. Allergan PLC
  • 40.2. Baxter International Inc
  • 40.3. Bayer AG
  • 40.4. Boehringer Ingelheim
  • 40.5. Cesca Therapeutics, Inc.
  • 40.6. F. Hoffmann-La Roche Ltd.
  • 40.7. Fujifilm Corporation
  • 40.8. Medtronic plc
  • 40.9. Merck KGaA
  • 40.10. Mimedx Group Inc
  • 40.11. Novartis AG
  • 40.12. Organogenesis, Inc.
  • 40.13. Osiris Therapeutics
  • 40.14. Pfizer, Inc.
  • 40.15. Takara Bio Inc.
  • 40.16. U.S. Stem Cell, Inc.
  • 40.17. Other Prominent Players